Core Viewpoint - The outbreak of Chikungunya fever in Shunde has led to a significant increase in confirmed cases, prompting a global alert and creating four major investment opportunities in related industries [1]. Group 1: Diagnostic Testing Companies (Short-term beneficiaries) - Da An Gene (002030) and Wanfu Biology (300482) are positioned to benefit from the surge in demand for diagnostic testing [3]. - Rundu Biotech (688193) is the only listed company in China focusing on RNA virus diagnostics, with a significant increase in orders expected due to the urgent need for Chikungunya virus nucleic acid testing kits [5]. - The government procurement demand for Rundu Biotech's products is clear, with a 200% increase in orders expected by July 2025 [5]. Group 2: Mosquito Control Companies (Interrupting transmission chain) - The leading mosquito repellent company in A-shares has a market share of 16.2% in electric mosquito repellent liquid, with a notable 80% increase in sales through Douyin [3]. - The company has a significant market share of over 60% for its mosquito repellent products, with plans to launch portable products in 2024 [4]. - Noposion (002215) has a high efficacy insecticide with over 90% knockdown rate against Aedes mosquitoes, winning a government project worth 30 million yuan in Foshan [6][7]. Group 3: Therapeutic Drug Companies (Symptom relief) - Tan Re Qing injection has been recommended in the Dengue fever treatment guidelines, potentially extending its use to Chikungunya fever treatment [8]. - Yiling Pharmaceutical (002603) has received approval for Lianhua Qingwen capsules as an auxiliary treatment for mosquito-borne diseases in Southeast Asia, with growing international demand [10]. Group 4: Vaccine Development Companies (Long-term layout) - Companies are collaborating with international pharmaceutical firms to develop vector-borne virus vaccines, with preclinical research for Chikungunya vaccine expected to start in 2025 [12]. - Watson Bio (300142) has an mRNA technology platform that is compatible with vector-borne vaccine development, indicating a strong potential for future vaccine projects [13].